

Original citation:

Stallard, Nigel and Kimani, Peter K. (2018) *Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials*. *Biometrika*, 105 (2). pp. 495-501. doi:[10.1093/biomet/asy004](https://doi.org/10.1093/biomet/asy004)

Permanent WRAP URL:

<http://wrap.warwick.ac.uk/97283>

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions.

This article is made available under the Creative Commons Attribution 4.0 International license (CC BY 4.0) and may be reused according to the conditions of the license. For more details see: <http://creativecommons.org/licenses/by/4.0/>

A note on versions:

The version presented in WRAP is the published version, or, version of record, and may be cited as it appears here.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk

Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials

BY NIGEL STALLARD AND PETER K. KIMANI

Warwick Medical School, University of Warwick, Coventry CV4 7AL, U.K.

n.stallard@warwick.ac.uk peter.k-u.kimani@warwick.ac.uk

SUMMARY

Multi-arm multi-stage clinical trials compare several experimental treatments with a control treatment, with poorly performing treatments dropped at interim analyses. This leads to inferential challenges, including the construction of unbiased treatment effect estimators. A number of estimators which are unbiased conditional on treatment selection have been proposed, but are specific to certain selection rules, may ignore the comparison to the control and are not all minimum variance. We obtain estimators for treatment effects compared to the control that are uniformly minimum variance unbiased conditional on selection with any specified rule or stopping for futility.

Some key words: Adaptive seamless design; Drop-the-loser design; Point estimation; Treatment selection.

1. INTRODUCTION

Multi-arm multi-stage clinical trials compare several treatments to a common control treatment in a single trial with treatments dropped at interim analyses if, based on observed data, they are not sufficiently promising. Such designs have been used by, for example, [MacArthur et al. \(2013\)](#) and [Barker et al. \(2014\)](#). The approach can yield sample size reduction and administrative savings relative to running several two-arm trials, but presents challenges in terms of statistical analysis similar to those of post-model selection inference ([Efron, 2014](#)).

Proposed analysis methods have mainly focused on frequentist hypothesis tests ([Thall et al., 1988, 1989](#); [Stallard & Todd, 2003](#); [Stallard & Friede, 2008](#); [Magirr et al., 2012](#); [Wason et al., 2017](#)), with less work on estimation. [Cohen & Sackrowitz \(1989\)](#) consider two-stage designs with the treatment with the highest observed stage 1 average continuing to stage 2, with equal variances for the averages for each treatment in stage 1 and the stage 2 treatment. They derive an estimator of the stage 2 treatment mean that is uniformly minimum variance conditionally unbiased given the observed ordering of stage 1 treatment means. [Bowden & Glimm \(2008\)](#) extend the method to allow different variances for the treatment means and continuation to stage 2 of the s treatments with the largest observed stage 1 means. They provide expressions for uniformly minimum variance conditionally unbiased estimators for the means for these s treatment arms, again conditioning on the ordering of the stage 1 averages. Like [Cohen & Sackrowitz \(1989\)](#), they do not consider estimation relative to a control group.

[Kimani et al. \(2013\)](#), [Bowden & Glimm \(2014\)](#) and [Robertson et al. \(2016\)](#) derive conditionally unbiased estimators for the difference between selected treatments and a control in multi-arm multi-stage trials. [Kimani et al. \(2013\)](#) allow for stopping for futility at stage 1 of a two-stage trial assuming common variances for averages in different arms in stage 1, while [Bowden & Glimm \(2014\)](#) and [Robertson et al. \(2016\)](#) allow for different variances in different arms and correlation between these respectively. [Bowden & Glimm \(2014\)](#) also allow for more than two stages. As discussed below, the [Kimani et al. \(2013\)](#) and [Robertson et al. \(2016\)](#) estimators are conditionally unbiased but not generally minimum variance. We obtain minimum variance conditionally unbiased estimators in these settings.

© 2018 Biometrika Trust

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

These methods present estimators that are unbiased conditional on selection of the treatment arms with the largest observed stage 1 averages, possibly with the additional condition that these means are sufficiently larger than that for the control. In practice, other selection rules may be used, such as in § 3 below. We show how uniformly minimum variance conditionally unbiased estimators may be obtained for comparisons with the control conditioning on a treatment not being dropped from the trial using any specified rule for selection or stopping for futility.

2. UNIFORMLY MINIMUM VARIANCE CONDITIONALLY UNBIASED ESTIMATION

2.1. A uniformly minimum variance conditionally unbiased estimator

Consider a multi-arm multi-stage clinical trial with up to r stages where, in stage j , patients are randomized to a control treatment, treatment 0, or experimental treatments, labelled i ($i \in \Omega_j$), with $\Omega_1 \supseteq \dots \supseteq \Omega_r$. Without loss of generality, label treatments such that $\Omega_j = \{1, \dots, s_j\}$ for some s_j ($j = 1, \dots, r$). Denoting the total number of experimental treatments, s_1 , by k , let $r_i = \max\{j : s_j \geq i\}$ ($i = 1, \dots, k$), so that treatment i is included in stages $1, \dots, r_i$, and set $r_0 = r$.

Let X_{ij} denote the stagewise average for treatment i in stage j ($i = 0, \dots, k; j = 1, \dots, r_i$), with $X_i = (X_{i1}, \dots, X_{ir_i})^T$, $X_j = (X_{0j}, \dots, X_{s_j j})^T$ and $\mathcal{X}_j = (X_1^T, \dots, X_j^T)^T$. Assume that the X_{ij} are jointly sufficient for μ_0, \dots, μ_k , with $X_{ij} \sim N(\mu_i, \tau_{ij}^{-1})$ independent with τ_{ij} known. Other cases, such as in § 3 below, may use normal approximations or estimated variances. Experimental treatments are selected to continue, along with the control, to stage $j + 1$ depending on \mathcal{X}_j according to some prespecified rule. Some possible rules are discussed below.

Define $\theta_i = \mu_i - \mu_0$ ($i = 1, \dots, k$). We wish to estimate θ_i ($i = 1, \dots, s_r$). In particular, we will obtain uniformly minimum variance conditionally unbiased estimators of $\theta_1, \dots, \theta_{s_r}$ conditional on the event, Q , that treatments $1, \dots, s_r$ are selected to continue to the end of the trial according to the prespecified selection rule.

Let $\tau_i = (\tau_{i1}, \dots, \tau_{ir_i})^T$, $\tau_i = \tau_{i1} + \dots + \tau_{ir_i}$, $Z_i = X_i^T \tau_i \tau_i^{-1}$ ($i = 0, \dots, k$), $Z = (Z_0, \dots, Z_k)^T$ and $\theta_{k+1} = \sum_{i=0}^k \tau_i \mu_i / \sum_{i=0}^k \tau_i$. The Appendix shows that θ_{k+1} is orthogonal to θ_i , in that the information matrix term $i_{\theta_i \theta_{k+1}} = 0$ (Cox & Reid, 1987) ($i = 1, \dots, k$) and Z is complete and sufficient for $\theta = (\theta_1, \dots, \theta_{k+1})^T$. Let $Y_i = X_{ir} - X_{0r}$ ($i = 1, \dots, s_r$); then Y_i is unbiased for θ_i and, since Y_i is independent of \mathcal{X}_{r-1} and hence of Q , is also conditionally unbiased for θ_i given Q . Thus, by the Rao–Blackwell theorem, $E(Y_i | Z, Q)$ is a uniformly minimum variance conditionally unbiased estimator for θ_i given Q ($i = 1, \dots, s_r$).

Since, given the specified selection rule, the event Q depends only on \mathcal{X}_{r-1} ,

$$E(Y_i | Z, Q) = \frac{\int_Q E(Y_i | Z, \mathcal{X}_{r-1}) f(\mathcal{X}_{r-1} | Z) d\mathcal{X}_{r-1}}{\int_Q f(\mathcal{X}_{r-1} | Z) d\mathcal{X}_{r-1}}, \tag{1}$$

with the integrals taken over the region Q corresponding to those \mathcal{X}_{r-1} for which treatments $1, \dots, s_r$ will be selected to continue to stage r . The denominator is the probability of Q given Z , which will be denoted by $\text{pr}(Q | Z)$.

As

$$\begin{pmatrix} X_{i1} \\ \vdots \\ X_{i,r_i-1} \\ Z_i \end{pmatrix} \sim N \left\{ \begin{pmatrix} \mu_i \\ \vdots \\ \mu_i \end{pmatrix}, \begin{pmatrix} \tau_{i1}^{-1} & 0 & \dots & 0 & \tau_i^{-1} \\ 0 & \tau_{i2}^{-1} & \ddots & \vdots & \vdots \\ \vdots & \ddots & \ddots & 0 & \vdots \\ 0 & \dots & 0 & \tau_{i,r_i-1}^{-1} & \vdots \\ \tau_i^{-1} & \dots & \dots & \dots & \tau_i^{-1} \end{pmatrix} \right\}$$

and, for $i \neq i'$ and any j, j' , X_{ij} is independent of $X_{i'j'}$ and $Z_{i'}$, we have that

$$f(\mathcal{X}_{r-1} | Z) = \prod_{i=0}^k \phi_{r_i-1} \{ (X_{i1}, \dots, X_{i,r_i-1})^T; \tilde{\mu}_i, \tilde{\Sigma}_i \}, \tag{2}$$

where $\phi_n(X; \mu, \Sigma)$ denotes the n -dimensional multivariate normal density with mean μ and variance matrix Σ , evaluated at X , with $\tilde{\mu}_i = (Z_i, \dots, Z_i)^T$ and $\tilde{\Sigma}_i$ having diagonal elements $(\tau_{i1}^{-1} - \tau_i^{-1}, \dots, \tau_{i,r_i-1}^{-1} - \tau_i^{-1})$ and all off-diagonal elements equal to $-\tau_i^{-1}$. If $r_i = 1$, X_{i1} given Z has a degenerate distribution, since $X_{i1} = Z_i$ and $\tau_{i1} = \tau_i$.

Since $Y_i = X_{ir} - X_{0r}$ and $X_{ir} = \tau_{ir}^{-1}(\tau_i Z_i - \sum_{j=1}^{r-1} X_{ij} \tau_{ij})$ ($i = 0, \dots, s_r$),

$$E(Y_i | Z, \mathcal{X}_{r-1}) = \tau_{ir}^{-1} \tau_i Z_i - \tau_{0r}^{-1} \tau_0 Z_0 - \sum_{j=1}^{r-1} (\tau_{ir}^{-1} \tau_{ij} X_{ij} - \tau_{0r}^{-1} \tau_{0j} X_{0j}).$$

Thus (1) gives

$$E(Y_i | Z, Q) = \tau_{ir}^{-1} \tau_i Z_i - \tau_{0r}^{-1} \tau_0 Z_0 - \text{pr}(Q | Z)^{-1} \int_Q \sum_{j=1}^{r-1} (\tau_{ir}^{-1} \tau_{ij} X_{ij} - \tau_{0r}^{-1} \tau_{0j} X_{0j}) f(\mathcal{X}_{r-1} | Z) d\mathcal{X}_{r-1}. \quad (3)$$

An important special case arises when the selection rule does not depend on X_0 , the observed averages for the control arm. In the integral over the event Q , the range of integration with respect to X_{ij} ($i = 1, \dots, k; j = 1, \dots, r_i$) then does not depend on X_0 and the integration with respect to the elements of X_0 , i.e., $X_{01}, \dots, X_{0,r-1}$, is over the whole real line. Thus

$$\text{pr}(Q | Z)^{-1} \int_Q \tau_{0r}^{-1} \sum_{j=1}^{r-1} X_{0j} \tau_{0j} f(\mathcal{X}_{j-1} | Z) d\mathcal{X}_{r-1} = \tau_{0r}^{-1} \sum_{j=1}^{r-1} \tau_{0j} E(X_{0j} | Z),$$

and since $E(X_{0j} | Z) = Z_0$ ($j = 1, \dots, r - 1$), we have

$$E(Y_i | Z, Q) = \tau_{ir}^{-1} \tau_i Z_i - \text{pr}(Q | Z)^{-1} \int_Q \tau_{ir}^{-1} \sum_{j=1}^{r-1} X_{ij} \tau_{ij} f(\mathcal{X}_{r-1} | Z) d\mathcal{X}_{r-1} - Z_0. \quad (4)$$

In this case the uniformly minimum variance conditionally unbiased estimator for θ_i is the difference between the uniformly minimum variance conditionally unbiased estimator of μ_i , which can be calculated ignoring the observed value of X_0 , and Z_0 , the usual uniformly minimum variance unbiased estimator of μ_0 , which does not depend on the selection.

The integrals in (3) generally cannot be evaluated using standard functions. A numerical approach is Monte Carlo integration with rejection sampling, simulating \mathcal{X}_{r-1} from (2), its conditional distribution given Z , accepting those in Q for the specified selection rule. This approach can be used for any selection rule with treatments proceeding to stage $j + 1$ dependent on \mathcal{X}_j .

2.2. Selection of the best-performing treatment in a two-stage trial

Much previous work on conditionally unbiased estimation in clinical trials with treatment selection has focused on the special case of $r = 2$ and $s_2 = 1$, with the experimental treatment having the largest observed stage 1 mean continuing along with the control to stage 2. Thus Q is the event $X_{11} > m$ with $m = \max(X_{21}, \dots, X_{k1})$. As Q is independent of X_0 , the uniformly minimum variance conditionally unbiased estimator for θ_1 is (4). Since treatments $2, \dots, k$ are observed in stage 1 only, we have $Z_i = X_{i1}$ ($i = 2, \dots, k$) so that the numerator and denominator in the fractional term in (4) are respectively $\tau_{12}^{-1} \tau_{11} \int_m^\infty X_{11} f(X_{11} | Z_1) dX_{11}$ and $\text{pr}(X_{11} > m | Z_1)$. As $X_{11} | Z_1 \sim N(Z_1, v_1)$ with $v_1 = \tau_{11}^{-1} - \tau_1^{-1}$, this integral and probability are $Z_1 \{1 - \Phi(\tilde{Z}_1)\} + v_1^{1/2} \phi(\tilde{Z}_1)$ (Todd et al., 1996) and $1 - \Phi(\tilde{Z}_1)$ respectively, where $\tilde{Z}_1 = (m - Z_1)v_1^{-1/2}$. Thus $E(Y_1 | Z, Q) = Z_1 - Z_0 - \tau_{11} \tau_{12}^{-1} v_1^{1/2} \phi(\tilde{Z}_1) / \{1 - \Phi(\tilde{Z}_1)\}$, confirming this to be the difference between the uniformly minimum variance conditionally unbiased estimator for μ_1 ignoring the control treatment given by Bowden & Glimm (2008) and Z_0 .

Kimani et al. (2013) consider a similar two-stage trial in which treatment 1 is selected if $X_{11} > m$ but continues to the second stage only if $X_{11} > X_{01} + c$ for some specified c , the trial otherwise stopping

early. In this case, Q is the event $X_{11} > \max(m, X_{01} + c)$. Since this depends on X_{01} , the form (3) must be used rather than (4) to give the uniformly minimum variance conditionally unbiased estimator of θ_1 . The integral in (3) is taken over X_{11} and X_{01} , but may be rewritten in terms of X_{11} and $(X_{11} - X_{01})$, noting that

$$\left(\begin{array}{c} X_{11} \\ X_{11} - X_{01} \end{array} \right) \Big| Z \sim N \left\{ \left(\begin{array}{c} Z_1 \\ Z_1 - Z_0 \end{array} \right), \left(\begin{array}{cc} v_1 & v_1 \\ v_1 & v_2 \end{array} \right) \right\}$$

with v_1 as above and $v_2 = v_1 + \tau_{01}^{-1} - \tau_0^{-1}$. Since Q is the rectangular region $\{X_{11} > m, (X_{11} - X_{01}) > c\}$, (3) is a truncated bivariate normal expectation and can be evaluated using Rosenbaum (1961) to obtain the uniformly minimum variance conditionally unbiased estimator

$$\tau_1 \tau_{12}^{-1} Z_1 - \tau_{11} \tau_{12}^{-1} E(X_{11} | Z, Q) - \tau_0 \tau_{02}^{-1} Z_0 - \tau_{01} \tau_{02}^{-1} E(X_{01} | Z, Q),$$

where $E(X_{11} | Z, Q) = v_1^{1/2} A + Z_1$ and $E(X_{01} | Z, Q) = v_1^{1/2} A - v_2^{1/2} B + Z_0$ with

$$A = \frac{\phi(a)\{1 - \Phi(\tilde{b})\} + \rho\phi(b)\{1 - \Phi(\tilde{a})\}}{U(a, b; \rho)}, \quad B = \frac{\rho\phi(a)\{1 - \Phi(\tilde{b})\} + \phi(b)\{1 - \Phi(\tilde{a})\}}{U(a, b; \rho)};$$

where $a = (m - Z_1)v_1^{-1/2}$, $b = (c - Z_1 + Z_0)v_2^{-1/2}$, $\tilde{a} = (a - \rho b)(1 - \rho^2)^{-1/2}$, $\tilde{b} = (b - \rho a)(1 - \rho^2)^{-1/2}$, $\rho^2 = v_1/v_2$ and $U(a, b; \rho) = \text{pr}(u_1 > a, u_2 > b)$ for $(u_1, u_2)^T$ standard bivariate normal with correlation ρ . This is not the estimator proposed by Kimani et al. (2013), which is conditionally unbiased but not minimum variance.

Robertson et al. (2016) also consider two-stage trials with early stopping for futility, though they do not assume equal variances and consider ranking by standardized observed stage 1 treatment effect estimates, $R_i = (X_{i1} - X_{01})(\tau_{i1}^{-1} + \tau_{01}^{-1})^{-1/2}$, assuming treatment 1 is selected if $R_1 > \max\{R_2, \dots, R_k, c\}$ for specified c . In constructing their estimators, they condition on statistics based on the observed treatment effects, $X_{ij} - X_{0j}$ ($i = 1, \dots, k; j = 1, 2$). Since these may not be sufficient, for example in the case of normal data with a common control, their estimator is also conditionally unbiased but not minimum variance; indeed they show that in the common variance case it has larger variance than the estimator proposed by Kimani et al. (2013).

3. NUMERICAL EXAMPLE

The ADVENT trial (MacArthur et al., 2013) was a two-stage study comparing 125 mg, 250 mg and 500 mg doses of crofelemer with a placebo in noninfectious chronic diarrhoea in HIV-seropositive patients. The primary endpoint was clinical response, defined as at most two watery stools per week during at least two of four weeks of treatment. At the end of stage 1, based on data from 200 patients randomized equally between the four treatment arms, a single dose of crofelemer would continue with the control to stage 2, with a further 150 patients randomized equally between these two groups. In the absence of safety concerns, the dose selected would be the lowest dose with an observed clinical response rate within two percentage points of the best-performing dose. Although not explicitly stated by MacArthur et al. (2013), we assume that the trial would have stopped at the first stage if the best-performing dose did not have observed clinical response rate at least two percentage points above the placebo. The trial was analysed using the method of Posch et al. (2005) to control the familywise Type I error rate, but apparently no attempt was made to obtain unbiased estimators of the treatment effect for the selected dose. The U.S. Food and Drug Administration (2012) report gives results of the two stages of the study. In stage 1, 50, 44, 54 and 46 patients received the placebo and the three doses respectively, with 1, 9, 5 and 9 patients in these groups showing clinical response. In stage 2, 88 and 92 further patients received the placebo and 125 mg crofelemer respectively, with 10 and 15 demonstrating clinical response. A naive estimate of the effect of the 125 mg dose relative to placebo is thus $24/136 - 11/138 = 0.097$.

Table 1. Simulated probability of selection and bias (with root mean squared error in parentheses), with all values multiplied by 100, for the estimator given by (3) and the naive estimator for θ_i conditional on selection of treatment i ($i = 1, \dots, 3$) for a range of μ values ($\mu_0 = 0.02$ in all cases)

(μ_1, μ_2, μ_3)	pr(selected)			Estimator from (3)			Naive estimator		
	1	2	3	θ_1	θ_2	θ_3	θ_1	θ_2	θ_3
(0.02, 0.02, 0.02)	8	5	4	-0.2 (1.5)	-0.2 (1.5)	-0.1 (1.5)	1.6 (2.0)	1.7 (2.2)	1.9 (2.3)
(0.02, 0.02, 0.2)	<1	<1	99	-0.4 (1.3)	-0.4 (1.4)	-0.7 (3.9)	1.7 (2.1)	1.7 (2.1)	-0.4 (3.7)
(0.02, 0.1, 0.2)	<1	14	86	-0.2 (1.5)	-0.7 (3.3)	-0.6 (3.9)	2.0 (2.6)	1.4 (3.1)	0.0 (3.6)
(0.02, 0.2, 0.2)	<1	61	39	-0.2 (0.9)	-0.7 (4.1)	-0.5 (4.2)	2.1 (2.4)	0.5 (3.6)	1.2 (3.7)
(0.1, 0.2, 0.2)	5	58	37	-0.6 (3.3)	-0.7 (4.1)	-0.5 (4.2)	2.4 (3.6)	0.6 (3.6)	1.2 (3.7)
(0.2, 0.2, 0.2)	46	31	23	-0.7 (4.2)	-0.5 (4.2)	-0.5 (4.3)	1.0 (3.6)	1.5 (3.8)	1.9 (3.9)

For illustrative purposes, we treat estimated event rates as asymptotically normally distributed with variances based on the observed responses in each group and stage and set $(X_{01}, \dots, X_{31}) = (0.02, 0.2045, 0.0926, 0.1956)$, $(\tau_{01}, \dots, \tau_{31}) = (2551, 270.4, 642.1, 292.3)$, $(X_{02}, X_{12}) = (0.1136, 0.1630)$ and $(\tau_{02}, \tau_{12}) = (873.7, 674.2)$. Based on these results, we obtained an estimate from (3), calculating the integrals using 100 000 simulations conditional on 125 mg being the lowest dose with observed clinical response rate within two percentage points of the best-performing dose, giving an estimate of 0.114.

Properties of the estimator (3) were assessed in a realistic setting via simulations based on the ADVENT trial. For a range of μ values, for each of 100 000 simulated trials, we simulated $B_{i1} \sim B(50, \mu_i)$ ($i = 0, \dots, 3$), adding or subtracting 1 if $B_{i1} = 0$ or 50 to enable variance estimation. We then set $X_{i1} = B_{i1}/50$ and $\tau_{i1}^{-1} = X_{i1}(1 - X_{i1})/50$ ($i = 0, \dots, 3$). For $I = \min\{i \in \{0, \dots, 3\} : X_{i1} \geq \max_{i' \neq 0, \dots, 3} \{X_{i'1}\} - 0.02\}$, the trial was assumed to stop at the end of stage 1 if $I = 0$; otherwise, we simulated $B_{i2} \sim B_i(75, \mu_i)$ ($i = 0, I$), again adding or subtracting 1 if $B_{i2} = 0$ or 75, and set $X_{i2} = B_{i2}/75$ and $\tau_{i2}^{-1} = X_{i2}(1 - X_{i2})/75$. The estimate from (3) for θ_I , conditional on treatment I being selected, was obtained using 10 000 Monte Carlo simulations to evaluate the integrals, and was compared with the naive estimator $(B_{I1} + B_{I2})/125 - (B_{01} + B_{02})/125$. Table 1 gives simulated selection probabilities and the bias and root mean squared error for the naive estimator and estimator (3). Bias estimates have standard error of at most 0.0002, with the exception of those for θ_1 when $\mu = (0.02, 0.02, 0.2, 0.2)^T$ and for θ_3 when $\mu = (0.02, 0.2, 0.2, 0.2)^T$, with standard errors of 0.04 and 0.03 respectively, and estimators for treatments selected with a probability of less than 0.01. Recall that if observed differences between treatments are small, the selection rule favours treatments with the lowest indices, explaining the differences in selection probabilities for treatments with the same mean.

The naive estimator is conditionally biased, overestimating the true effect. The bias is relatively small, but in some cases it is, like the difference between the naive and new estimates for the ADVENT data reported above, close to the difference in clinical response rates of two percentage points considered important in the trial design. Only settings with $\mu = (0.02, 0.02, 0.02, 0.2)^T$ and $(0.02, 0.02, 0.1, 0.2)^T$, where the highest dose is nearly always selected, have bias near zero. The estimator (3) has bias near zero, though given that the derivation is based on assumed normality with known variance, it may not be unbiased; the simulated bias is negative in all cases, suggesting that the true treatment effect is slightly underestimated. The root mean squared errors of the two estimators are similar, though with some suggestion that the naive estimator has slightly smaller mean squared error in situations in which it has larger bias, consistent with theoretical results in settings in which the single most promising treatment is selected (Stallard et al., 2008; Bauer et al., 2010). Given the simulation results, it is interesting that the estimate from (3) using the observed ADVENT trial data is larger than the naive estimate. This appears to be due to the large difference between X_{01} and X_{02} , the placebo arm means in the two stages. A full analysis might involve investigation of possible causes for this difference.

The estimators proposed by Kimani et al. (2013) and Robertson et al. (2016) were not included in the simulations as they are not applicable for the selection rule used. We conducted 10^6 additional simulations

with $r = k = 2$ and $X_{ij} \sim N(0, 1)$ ($i = 0, 1, 2; j = 1, 2$), selecting the treatment with the largest X_{i1} to continue to stage 2 provided $X_{i1} - X_{01} > c$, when the Kimani et al. (2013) estimator is conditionally unbiased and has smaller mean squared error than that of Robertson et al. (2016). If $c \rightarrow -\infty$, so there is no stopping for futility, the Kimani et al. (2013) estimator and (3) correspond, with root mean squared error of 1.08. For $c = 0$, the two estimators have root mean squared error of 1.23 and 1.21 respectively, with these increasing to 1.34 and 1.31 respectively for $c = 2$. The probabilities of stopping for futility in these two cases are 0.64 and 0.87.

4. DISCUSSION

The method proposed gives uniformly minimum variance conditionally unbiased estimators in multi-arm multi-stage clinical trials. Estimators are obtained for treatment effects relative to the control for treatments continuing to the end of the trial conditional on the event, Q , that these treatments are selected to do so. The conditioning event is weaker than that considered by Bowden & Glimm (2008) and Cohen & Sackrowitz (1989), who condition on the ordering of stage 1 treatment means. We consider conditioning on Q to be appropriate since decisions regarding effectiveness of treatments are likely to depend on treatments continuing to the end of the trial but not on the ordering of continuing treatments at earlier analyses. The conditionally unbiased estimators are identical for a two-stage design with only the best-performing treatment continuing along with the control to stage 2, as shown in § 2.2 above.

We have considered the total number of treatments and selection rule to be specified in advance. Others have proposed more flexible approaches, such as in the STAMPEDE trial (Sydes et al., 2012), where treatment arms were added during the trial. Our method might not yield conditionally unbiased estimators in such a trial. In a fully flexible approach, it is not clear that it is even possible to define the bias, as this would be an expectation over an unspecified sample space.

ACKNOWLEDGEMENT

We thank the referees for their comments and the Medical Research Council for funding.

APPENDIX

Construction of sufficient statistics for $\theta_1, \dots, \theta_{k+1}$

Let θ_{k+1} be orthogonal to θ_i , that is, the information matrix term $i_{\theta_i \theta_{k+1}} = 0$ ($i = 1, \dots, k$) (Cox & Reid, 1987), and write $\mu_0 = \sum_{j=1}^{k+1} d_j \theta_j$ for some d_j ($j = 1, \dots, k+1$). Since we may scale θ_{k+1} arbitrarily and retain orthogonality, set $d_{k+1} = 1$ to get $\mu_0 = \sum_{j=1}^k d_j \theta_j + \theta_{k+1}$ and

$$\mu_i = \sum_{j=1}^k d_j \theta_j + \theta_{k+1} + \theta_i \quad (i = 1, \dots, k). \quad (\text{A1})$$

Let $X = (X_0^T, \dots, X_k^T)^T$; then $E(X) = \Lambda \theta$ where Λ is a $(\sum_{i=0}^k r_i) \times (k+1)$ matrix with blocks of r_i rows equal to $(d_1, \dots, d_k, 1) + 1_i$ ($i = 0, \dots, k$); here 1_i denotes the $(k+1)$ row vector with element i equal to 1 ($i = 1, \dots, k$) and other elements equal to 0, and $1_0 = (0, \dots, 0)^T$. We have $\text{var}(X) = T$, diagonal with elements $(\tau_{01}^{-1}, \dots, \tau_{0r_0}^{-1}, \dots, \tau_{k1}^{-1}, \dots, \tau_{kr_k}^{-1})$. The likelihood is proportional to $\exp\{(X - \Lambda \theta)^T T^{-1} (X - \Lambda \theta)\} = g(X) h(\theta) \exp(-2X^T T^{-1} \Lambda \theta)$, for some $g(X)$ and $h(\theta)$. Thus $X^T T^{-1} \Lambda$ is complete and sufficient for θ (Lehmann & Romano, 2005, § 4.3). Denoting $X^T T^{-1} \Lambda$ by $(W_1, \dots, W_{k+1})^T$, we have $W_{k+1} = \sum_{i=0}^k X_i^T \tau_i = \sum_{i=0}^k Z_i \tau_i$ and

$$W_i = d_i \sum_{i'=0}^k X_{i'}^T \tau_{i'} + X_i^T \tau_i = d_i \sum_{i'=0}^k Z_{i'} \tau_{i'} + Z_i \tau_i \quad (i = 1, \dots, k). \quad (\text{A2})$$

For orthogonality $(\partial \Lambda \theta / \partial \theta_i) T^{-1} (\partial \Lambda \theta / \partial \theta_{k+1}) = d_i \sum_{i'=0}^k \tau_{i'} + \tau_i = 0$, so $d_i = -\tau_i / \sum_{i'=0}^k \tau_{i'}$ and, from (A1) and (A2), $\theta_{k+1} = \sum_{i=0}^k \tau_i \mu_i / \sum_{i=0}^k \tau_i$, $W_{k+1} = \sum_{i=0}^k Z_i \tau_i$ and $W_i = \tau_i Z_i - \tau_i \sum_{i'=0}^k Z_{i'} \tau_{i'} / \sum_{i'=0}^k \tau_{i'}$ ($i = 1, \dots, k$), so Z is complete and sufficient.

With no selection, i.e., $s_r = k$, Z_i and $Z_i - Z_0$ are the usual uniformly minimum variance unbiased estimators for μ_i and θ_i ($i = 1, \dots, k$). By the factorization theorem, sufficient statistics are the same for the conditional and unconditional likelihoods, so Z is also sufficient in this case.

REFERENCES

- BARKER, K. L., JAVAID, M. K., NEWMAN, M., LOWE, C. M., STALLARD, N., CAMPBELL, H., GANDHI, V. & LAMB, S. (2014). Physiotherapy rehabilitation for osteoporotic vertebral fracture (PROVE): Study protocol for a randomised controlled trial. *Trials* **15**, 22.
- BAUER, P., KÖNIG, F., BRANNATH, W. & POSCH, M. (2010). Selection and bias — two hostile brothers. *Statist. Med.* **29**, 1–13.
- BOWDEN, J. & GLIMM, E. (2008). Unbiased estimation of selected means in two-stage trials. *Biomet. J.* **50**, 515–27.
- BOWDEN, J. & GLIMM, E. (2014). Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-loser trials. *Biomet. J.* **56**, 332–49.
- COHEN, A. & SACKROWITZ, H. B. (1989). Two stage conditionally unbiased estimators of the selected mean. *Statist. Prob. Lett.* **8**, 273–8.
- COX, D. & REID, N. (1987). Parameter orthogonality and approximate conditional inference (with Discussion). *J. R. Statist. Soc. B* **49**, 1–39.
- EFRON, B. (2014). Estimation and accuracy after model selection. *J. Am. Statist. Assoc.* **109**, 991–1007.
- KIMANI, P., TODD, S. & STALLARD, N. (2013). Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. *Statist. Med.* **32**, 2893–910.
- LEHMANN, E. & ROMANO, J. (2005). *Testing Statistical Hypotheses*. New York: Springer, 3rd ed.
- MACARTHUR, R. D., HAWKINS, T. N., BROWN, S. J., LAMARCA, A., CLAY, P. G., BARRETT, A. C., BORTEY, E., PATERSON, C., GOLDEN, P. L. & FORBES, W. P. (2013). Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): A randomized, double-blind, placebo-controlled, two-stage study. *HIV Clin. Trials* **14**, 261–73.
- MAGIRR, D., JAKI, T. & WHITEHEAD, J. (2012). A generalised Dunnett test for multi-arm, multi-stage clinical studies with treatment selection. *Biometrika* **99**, 494–501.
- POSCH, M., KOENIG, F., BRANSON, M., BRANNATH, W., DUNGER-BALDAUF, C. & BAUER, P. (2005). Testing and estimation in flexible group sequential designs with adaptive treatment selection. *Statist. Med.* **24**, 3697–714.
- ROBERTSON, D. S., PREVOST, A. T. & BOWDEN, J. (2016). Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules. *Statist. Med.* **35**, 3907–22.
- ROSENBAUM, S. (1961). Moments of a truncated bivariate normal distribution. *J. R. Statist. Soc. B* **23**, 405–8.
- STALLARD, N. & FRIEDE, T. (2008). A group-sequential design for clinical trials with treatment selection. *Statist. Med.* **27**, 6209–27.
- STALLARD, N. & TODD, S. (2003). Sequential designs for phase III clinical trials incorporating treatment selection. *Statist. Med.* **22**, 689–703.
- STALLARD, N., TODD, S. & WHITEHEAD, J. (2008). Estimation following selection of the largest of two normal means. *J. Statist. Plan. Infer.* **138**, 1629–38.
- SYDES, M. R., PARMAR, M. K. B., MASON, M. D., CLARKE, N. W., AMOS, C., ANDERSON, J., DE BONO, J., DEARNALEY, D. P., DWYER, J., GREEN, C. et al. (2012). Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: A multi-arm multi-stage randomized controlled trial. *Trials* **13**, 168.
- THALL, P. F., SIMON, R. & ELLENBERG, S. S. (1988). Two-stage selection and testing designs for comparative clinical trials. *Biometrika* **75**, 303–10.
- THALL, P. F., SIMON, R. & ELLENBERG, S. S. (1989). A two-stage design for choosing among several experimental treatments and a control in clinical trials. *Biometrics* **45**, 537–47.
- TODD, S., WHITEHEAD, J. & FACEY, K. M. (1996). Point and interval estimation following a sequential clinical trial. *Biometrika* **83**, 453–61.
- U.S. FOOD AND DRUG ADMINISTRATION (2012). *Application Number 202292Orig1s000 Statistical Review*. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000StatR.pdf. Accessed 1 Feb 2017.
- WASON, J., STALLARD, N., BOWDEN, J. & JENNISON, C. (2017). A multi-stage drop-the-losers design for multi-arm clinical trials. *Statist. Meth. Med. Res.* **26**, 508–24.

[Received on 13 September 2017. Editorial decision on 7 January 2018]